CATEGORIES: Research | Vitaccess

CMT&ME APP Adds New Medical Profile

by | Jan 6, 2020 | 0 comments

Did you know you can now store your CMT data at your fingertips? The CMT&ME app, developed by Vitaccess, has updated the app to include a brand new medical profile. To update the app, go to your app store and click update. 

In collaboration with our industry partners Pharnext and Vitaccess, we are thrilled to bring to you new features of the CMT&Me App. 

“This two-year study, which has been launched in 6 countries, was built for you and by you, the patients,” says Dr. Youcef Boutalbi, Pharnext Medical Affairs Director at the groundbreaking HNF Movement is Medicine™ Summit Crowd-Design Workshop on November 8-9, 2019. 

Currently this is the only mobile App for patients to record details on their diagnosis, list current or prior medications or participation in clinical trials, and log in regularly to report on symptoms, such as pain, falls, sleep, and so much more. 

This vital partnership gives our members the opportunity for their voices to be heard! By sharing your daily or weekly experiences and challenges, you are participating in very important research that will help Pharnext and the entire CMT community accelerate therapies to address your unmet medical needs, expand the knowledge of what you, as patients, face. Most importantly, it will provide a portal to store your data to refer back to or even share with your doctors. 

Allison Moore, Founder and CEO of HNF, has worked closely with Dr. Mark Larkin, Founder and CEO of Vitaccess, to disseminate CMT&Me research findings at global medical conferences to increase awareness of the CMT patient experience and advise regulators and payers (ie. insurance companies) on the impact CMT has on quality of life. The latest poster sessions Mark and Allison were highlighted at the AANEM annual conference in Austin, TX. 

  • Diversity in the Charcot-MarieTooth Disease Population in the United Kingdom and United States: Insights from a Digital Real-World Observational Study 
  • Treatment of Charcot-Marie-Tooth Disease in the United Kingdom and United States: Insights from a Digital Real-World Observational Study 

The CMT&Me App has shed additional insights into this grossly underserved community and the unmet need of medical care and treatments for our patient community. Pharnext, Vitaccess and HNF recognize the urgency of getting drugs approved and commercialized for CMT, so don’t wait, join today! 



Learn more on this topic

Related Blog Posts

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news